Company intelligence / Profile preview

Heron Therapeutics, Inc.

Cary, North Carolina, United Statesprnewswire.com ↗

Ownership: Public · HRTX
Development stage: Commercial

Overview

Heron Therapeutics has successfully commercialized multiple products including ZYNRELEF for postoperative pain, CINVANTI for CINV, SUSTOL for CINV, and APONVIE for PONV. The company received FDA approval for ZYNRELEF Vial Access Needle in September 2024 and for a supplemental New Drug Application for ZYNRELEF in January 2024.

Therapeutic areas: GastroenterologyOncologyNeurology
Modalities: Extended-release drug formulationspolymer-based drug delivery
Industry: Biotech

Drug pipeline

5 assets

aprepitant/bupivacaine/meloxicam

4 more assets in the full pipeline.

Request access →

Partnerships

CrossLink Life Sciences

Financials

Market cap: $61M
Total revenue: $37.7M
Enterprise value: $166.7M

Beyond the preview

Go deeper on Heron Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heron Therapeutics, Inc..

Explore the full profile